Status:

WITHDRAWN

A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo

Lead Sponsor:

Veloxis Pharmaceuticals

Conditions:

Chemotherapy-induced Peripheral Neuropathy

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

To evaluate the efficacy and safety of ART-123 on sensory symptoms of oxaliplatin-induced peripheral neuropathy (OIPN) in patients with unresectable metastatic colorectal cancer who receive oxaliplati...

Detailed Description

To compare the efficacy and safety of ART-123 (low and high dose) to placebo on sensory symptoms of oxaliplatin-induced peripheral neuropathy (OIPN) in patients with unresectable metastatic colorectal...

Eligibility Criteria

Inclusion

  • 18 years of age or older
  • Unresectable metastatic colorectal cancer; pathologically confirmed adenocarcinoma of the colon or rectum
  • ECOG performance status of 0 or 1
  • The most recent laboratory findings (including for liver and kidney) within 14 days prior to randomization remain within acceptable ranges
  • Willingness of the patient and the sexual partner to use a highly effective contraceptive method during the course of the study
  • Able to sufficiently understand the clinical study and give written informed consent

Exclusion

  • Prior treatment history with nerve toxic chemotherapeutic agent
  • Peripheral neuropathy or central nervous system damage
  • Psychiatric disorder
  • History of major hemorrhage
  • High risk of hemorrhage
  • History of other malignancies
  • Active ulcer
  • Patients using anti-coagulants and fibrinolytic drugs
  • Active Hepatitis B, or known HBs antigen positive
  • Prior treatment history with thrombomodulin alfa
  • Administration of another investigational medicinal product within 30 days prior to randomization
  • Patient is pregnant (positive urine human chorionic gonadotropin) or breastfeeding or intends to get pregnant during the Treatment period
  • Patients otherwise deemed as inappropriate to participate in the study by the Investigator

Key Trial Info

Start Date :

October 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2024

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04492436

Start Date

October 1 2021

End Date

July 1 2024

Last Update

February 18 2022

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo | DecenTrialz